OncRef

Clinical Trial: NCT05786430

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Yonsei University
Information Provided By:Yonsei University
Last Update Posted:2026-10-07

Study Overview

Brief Summary

This trial is Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients with EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to prior lazertinib.

Official Title

Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib (LUCAS)

Conditions

Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: Lazertinib/Pemetrexed/Carboplatin

Other Study ID Numbers

  • 4-2022-1142

Start Date (Actual)

2023-04-07

Primary Completion Date (Actual)

2026-08-23

Study Completion Date (Actual)

2026-08-23

Enrollment (Actual)

65

Study Type

Interventional

Phase

Phase 2